Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Objectively identified comorbidities in COPD: impact on pulmonary rehabilitation outcomes

Rafael Mesquita, Lowie E.G.W. Vanfleteren, Frits M.E. Franssen, Janeli Sarv, Ziad Taib, Miriam T.J. Groenen, Swetlana Gaffron, Piet L.B. Bruijnzeel, Fabio Pitta, Emiel F.M. Wouters, Martijn A. Spruit
European Respiratory Journal 2015 46: 545-548; DOI: 10.1183/09031936.00026215
Rafael Mesquita
1Dept of Research and Education, Centre of Expertise for Chronic Organ Failure (CIRO+), Horn, The Netherlands
2Dept of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands
6Both authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rafael Mesquita
  • For correspondence: rafaelmesquita14@ymail.com
Lowie E.G.W. Vanfleteren
1Dept of Research and Education, Centre of Expertise for Chronic Organ Failure (CIRO+), Horn, The Netherlands
2Dept of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands
6Both authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frits M.E. Franssen
1Dept of Research and Education, Centre of Expertise for Chronic Organ Failure (CIRO+), Horn, The Netherlands
2Dept of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janeli Sarv
3Respiratory, Infections and Autoimmunity (RIA) IMED, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ziad Taib
3Respiratory, Infections and Autoimmunity (RIA) IMED, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam T.J. Groenen
1Dept of Research and Education, Centre of Expertise for Chronic Organ Failure (CIRO+), Horn, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Swetlana Gaffron
4Analytics, Viscovery Software GmbH, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piet L.B. Bruijnzeel
3Respiratory, Infections and Autoimmunity (RIA) IMED, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabio Pitta
5Laboratory of Research in Respiratory Physiotherapy, Dept of Physiotherapy, State University of Londrina (UEL), Londrina, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emiel F.M. Wouters
1Dept of Research and Education, Centre of Expertise for Chronic Organ Failure (CIRO+), Horn, The Netherlands
2Dept of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martijn A. Spruit
1Dept of Research and Education, Centre of Expertise for Chronic Organ Failure (CIRO+), Horn, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Patients with COPD and multiple comorbidities can still benefit from pulmonary rehabilitation http://ow.ly/LXAWc

To the Editor:

Pulmonary rehabilitation (PR) is a comprehensive intervention recognised as a core component in the treatment of patients with chronic obstructive pulmonary disease (COPD) [1]. Comorbidities are highly prevalent in patients with COPD entering PR [2–4], which may be associated with the change in exercise performance and health status after PR [3–5]. Nonetheless, previous studies used self-reported and/or chart-based comorbidities, and only the impact of individual comorbidities or arbitrarily grouped comorbidities were studied [3, 4].

Vanfleteren et al. [2] identified five clusters based on the presence of 13 objectively diagnosed comorbidities in patients with COPD. The aims of the present study were: 1) to investigate the impact of 13 individual objectively identified comorbidities on changes in functional exercise performance and health status following PR in patients with COPD; and 2) to investigate the impact of the five comorbidity clusters on these changes.

Patients adhered to the following inclusion criteria: Global Initiative for Chronic Obstructive Lung Disease grades 2–4 [6], 40–80 years of age, clinically stable state, and a smoking history of ≥10 pack-years or relevant occupational exposure. Patients were considered ineligible if they had any disease and/or condition that could compromise the initial assessments. All participants gave written informed consent, and the study was approved by the local ethics and review boards (MEC 10-3-067). The baseline data from this study have been published before [2].

Participants enrolled in an 8-week inpatient (5 days·week−1) or 14-week outpatient (3 days·week−1) comprehensive PR programme [7]. During initial evaluation, 13 comorbidities were diagnosed using objective measures and according to international criteria, and five comorbidity clusters were identified. Further details can be found in Vanfleteren et al. [2]. Self-reported comorbidities were assessed using the Charlson comorbidity index [8]. The total score on this index was not adjusted for age and did not include COPD as comorbidity, as previously suggested [3, 4].

Functional exercise capacity (the 6-min walk test and the constant work rate cycling test (CWRT), performed on a cycle ergometer) and health status (St George's Respiratory Questionnaire (SGRQ)) were assessed before and after PR. An improvement in: the 6-min walking distance (6MWD) of ≥30 m [9]; the CWRT time of ≥100 s [10]; and a decrease in SGRQ total score of ≥4 [11] were considered clinically relevant. Logistic regression models adjusted for age, sex, forced expiratory volume in the 1 s (FEV1) and the baseline 6MWD, CWRT time or SGRQ total score were used to identify the predictive role of comorbidities on meaningful improvements following PR. Statistical significance was considered at p≤0.01.

255 patients with COPD were recruited, but 42 patients were ineligible [2]. 213 participants (59% male, mean age 64±7 years, mean FEV1 51±17% predicted) started PR, of which 19 (9%) participants dropped out. No differences were found between patients who dropped out and patients who completed the programme. The proportion of patients undergoing inpatient or outpatient rehabilitation was comparable between clusters (p=0.37).

The mean change (95% CI) for 6MWD, cycle endurance time, and health status scores were 30 m (23–38 m), 202 s (155–248 s) and −4.0 (−6.0–−2.0), respectively, and proved to be clinically meaningful and statistically significant. Logistic regression models revealed that none of the 13 objectively diagnosed comorbidities changed the likelihood for a clinically meaningful change in 6MWD, CWRT time or SGRQ total score following PR (fig. 1). When the number of objectively identified comorbidities (none, 1 and >1) were taken into account in logistic regression models, none of the analyses reached statistical significance (fig. 1). Similar results were found for the total score in the Charlson index (0, 1 or ≥2 points). With the “less comorbidity” cluster as reference, none of the clusters had a significantly different likelihood to achieve the minimal important change on the different outcomes. Only the “psychologic” cluster had a significantly higher likelihood for clinically meaningful change in 6MWD (fig. 1).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Predictive role of individual objectively identified comorbidities (a–c), clusters of objectively identified comorbidities (d–f), and the number of objectively identified comorbidities (h–i) on meaningful improvements, after pulmonary rehabilitation, in: a, d and g) the 6-min walk test (n=187 due to missing data); b, e and h) constant work rate test (n=174 due to missing data); and c, f and g) St George's Respiratory Questionnaire (n=151 due to missing data). Models adjusted for age, sex, forced expiratory volume in 1 s and the baseline value in each outcome measure. CKD: chronic kidney disease; MI: myocardial infarction. #: participants showing symptoms; ¶: reference.

The present study showed that the presence of individual or clusters of objectively identified comorbidities do not, generally, influence the likelihood of having a clinically meaningful change in 6MWD, CWRT time and/or SGRQ total score following PR in patients with COPD. These data emphasise that patients with COPD are still able to obtain significant and clinically relevant improvements in functional exercise capacity and health status after PR, irrespective of the presence of comorbidities.

Osteoporosis, heart disease and metabolic disease have been shown to be positively or negatively associated with changes in 6MWD and SGRQ scores following PR [3, 4]. We were not able to corroborate these findings. In our study, comorbidities were assessed using objective measures, while most previous studies used “self-reports” or data from medical records [3, 4]. Moreover, previous studies used a different threshold to classify an improvement in 6MWD as clinically relevant (i.e. 54 m) [3, 4].

Surprisingly, only the “psychologic” cluster was associated with a higher likelihood of achieving meaningful improvements in 6MWD compared to the “less comorbidity” cluster. The “psychologic” cluster is characterised by more baseline symptoms of anxiety and depression [2]. Previously, Von Leupoldt et al. [12] showed that more symptoms of anxiety and depression are associated with reduced exercise capacity. We believe that more symptoms of anxiety and/or depression may lead to excessive sensitiveness to dyspnoea, which in turn can work as a limiting factor for exercise. As suggested by Maurer et al. [13], the multidisciplinary and comprehensive approach adopted in PR programmes may help to desensitise patients who are excessively sensitive to dyspnoea, and this can translate as greater improvements in terms of exercise capacity. A reduction of anxiety and depression symptom scores, commonly achieved after PR, may, in turn, contribute to dyspnoea desensitisation [13].

The presence of common comorbidities in patients with COPD has been used frequently as an exclusion criterion for PR [1]. In the present study, only patients with comorbidities potentially interfering with the safety or usefulness of the programme were excluded, such as unstable heart disease or uncurated malignancies. Our study proves that common comorbidities, in general, do not influence the likelihood of improving following PR. Moreover, exercise has been suggested as the cornerstone of PR in COPD [1], and this strategy has been used as therapy in other chronic diseases as well, such as cardiovascular and metabolic diseases [14, 15]. Therefore, patients with COPD and the above mentioned comorbidities may benefit even more from PR.

The patients included in the current analysis were those referred for PR, which can compromise the generalisability of our findings. Nevertheless, Vanfleteren et al. [2] have previously shown that these patients have similar characteristic compared to patients from other studies. Another possible limitation is that some analyses may be underpowered. Therefore, the current findings are more hypothesis-generating than definitive. Studies with large samples and preferably from different centres are desirable.

In summary, comorbidities do not seem to preclude patients with COPD from obtaining significant and clinically meaningful improvements in functional exercise capacity and health status following PR. Complex patients with COPD and comorbidities should not be withheld from PR.

Footnotes

  • Support statement: R. Mesquita is supported by CNPq, Conselho Nacional de Desenvolvimento Científico e Tecnológico – Brazil (246704/2012-8). This study was supported by a research grant from AstraZeneca. Funding information for this article has been deposited with FundRef.

  • Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

  • Received January 21, 2015.
  • Accepted April 6, 2015.
  • Copyright ©ERS 2015

References

  1. ↵
    1. Spruit MA,
    2. Singh SJ,
    3. Garvey C, et al.
    An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13–e64.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Vanfleteren LE,
    2. Spruit MA,
    3. Groenen M, et al.
    Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728–735.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Crisafulli E,
    2. Costi S,
    3. Luppi F, et al.
    Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63: 487–492.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Crisafulli E,
    2. Gorgone P,
    3. Vagaggini B, et al.
    Efficacy of standard rehabilitation in COPD outpatients with comorbidities. Eur Respir J 2010; 36: 1042–1048.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Ambrosino N,
    2. Venturelli E,
    3. de Blasio F, et al.
    A prospective multicentric study of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease and different clinical phenotypes. Respiration 2015; 89: 141–147.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Vestbo J,
    2. Hurd SS,
    3. Agusti AG, et al.
    Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–365.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Spruit MA,
    2. Vanderhoven-Augustin I,
    3. Janssen PP, et al.
    Integration of pulmonary rehabilitation in COPD. Lancet 2008; 371: 12–13.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Charlson ME,
    2. Pompei P,
    3. Ales KL, et al.
    A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Holland AE,
    2. Spruit MA,
    3. Troosters T, et al.
    An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44: 1428–1446.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Laviolette L,
    2. Bourbeau J,
    3. Bernard S, et al.
    Assessing the impact of pulmonary rehabilitation on functional status in COPD. Thorax 2008; 63: 115–121.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Jones PW
    . St George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75–79.
    OpenUrlCrossRefWeb of Science
  12. ↵
    1. von Leupoldt A,
    2. Taube K,
    3. Lehmann K, et al.
    The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. Chest 2011; 140: 730–736.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Maurer J,
    2. Rebbapragada V,
    3. Borson S, et al.
    Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008; 134: 43S–56S.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Mezzani A,
    2. Hamm LF,
    3. Jones AM, et al.
    Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation, and the Canadian Association of Cardiac Rehabilitation. J Cardiopulm Rehabil Prev 2012; 32: 327–350.
    OpenUrlCrossRefPubMed
  15. ↵
    1. O'Hagan C,
    2. De Vito G,
    3. Boreham CA
    . Exercise prescription in the treatment of type 2 diabetes mellitus: current practices, existing guidelines and future directions. Sports Med 2013; 43: 39–49.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 46 Issue 2 Table of Contents
European Respiratory Journal: 46 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Objectively identified comorbidities in COPD: impact on pulmonary rehabilitation outcomes
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Objectively identified comorbidities in COPD: impact on pulmonary rehabilitation outcomes
Rafael Mesquita, Lowie E.G.W. Vanfleteren, Frits M.E. Franssen, Janeli Sarv, Ziad Taib, Miriam T.J. Groenen, Swetlana Gaffron, Piet L.B. Bruijnzeel, Fabio Pitta, Emiel F.M. Wouters, Martijn A. Spruit
European Respiratory Journal Aug 2015, 46 (2) 545-548; DOI: 10.1183/09031936.00026215

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Objectively identified comorbidities in COPD: impact on pulmonary rehabilitation outcomes
Rafael Mesquita, Lowie E.G.W. Vanfleteren, Frits M.E. Franssen, Janeli Sarv, Ziad Taib, Miriam T.J. Groenen, Swetlana Gaffron, Piet L.B. Bruijnzeel, Fabio Pitta, Emiel F.M. Wouters, Martijn A. Spruit
European Respiratory Journal Aug 2015, 46 (2) 545-548; DOI: 10.1183/09031936.00026215
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Association between immunosuppressants and outcomes of COVID-19
Show more Agora

Research letters

  • Mitochondrial DNA as biomarker of survival in RA-ILD
  • Lung transplantation for cystic fibrosis before and after availability of elexacaftor/tezacaftor/ivacaftor
  • Elexacaftor-tezacaftor-ivacaftor and circulating neutrophil counts in CF
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society